Antiparasitic agent-10 (Compound 94) is a potent anti-parasitic agent specifically designed to target and combat parasitic infections. It demonstrates notable anti-schistosomal activity, particularly against adults of Schistosoma mansoni. As a result, this compound holds significant potential for utilization in Schistosomiasis research as a viable treatment option [1].
Antiparasitic agent-9 (compound 47) is a highly active and orally administered antiparasitic agent, exhibiting potent antiparasitic efficacy against the human parasite [1].
Antiparasitic agent-5 (compound 8h) exhibits potent selectivity as an antiparasitic agent against Leishmania infantum (L. infantum), with an IC50 value of 2.50 μM. Additionally, this compound displays cytotoxic effects on HepG2 cells with a CC50 value of 6.78 μM [1].
Antiparasitic agent-7 (compound 5d) displays specific antiparasitic activity against Leishmania infantum (L. infantum), exhibiting an IC50 value of 2.85 μM. Additionally, Antiparasitic agent-7 demonstrates cytotoxicity against HepG2 cells with a CC50 value of 10.61 μM [1].
Antifungal agent 26, a derivative of gramicidin A, exhibits antifungal, antiviral, and antiparasitic activities through binding with polysaccharides containing D-mannose (Man) in pathogens.
Hygrolidin is a macrocyclic lactone originally isolated from S. hygroscopicus. It inhibits proliferation of a variety of cancer cell lines, including DLD-1 colon cancer, LNCaP prostate cancer, and K562 leukemia cells (IC50s = 2.9, 5.2, and 33 ng/ml, respectively). Hygrolidin induces the expression and levels of p21 in DLD-1 cells, but not WI-38 fibroblasts, and leads to cell accumulation in the G1 and S phases without inducing apoptosis. It has antiparasitic activity against T. cruzi, L. donovani, and T. b. brucei but also induces cytotoxicity in HepG2 cells (IC50s = 1.1, 72.5, 77, and 24.5 nM, respectively).